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Abstract
Background: Cigarette smoke exposure is the major risk factor for developing COPD. Presently, available COPD
treatments focus on suppressing inflammation and providing bronchodilation. However, these options have varying
efficacy in controlling symptoms and do not reverse or limit the progression of COPD. Treatments strategies using
bacterial-derived products have shown promise in diseases characterized by inflammation and immune dysfunction.
This study investigated for the first time whether a novel immunotherapy produced from inactivated Klebsiella
(hereafter referred to as KB) containing all the major Klebsiella macromolecules, could attenuate cigarette smoke
exposure-induced immune responses. We hypothesized that KB, by re-directing damaging immune responses, would
attenuate cigarette smoke-induced lung inflammation and bronchoalveolar (BAL) cytokine and chemokine production.
Methods: KB was administered via a subcutaneous injection prophylactically before initiating a 3-week acute nose-only
cigarette smoke exposure protocol. Control mice received placebo injection and room air. Total BAL and differential cell
numbers were enumerated. BAL and serum were analysed for 31 cytokines, chemokines, and growth factors. Lung tissue
and blood were analysed for Ly6CHI monocytes/macrophages and neutrophils. Body weight and clinical scores were
recorded throughout the experiment.
Results: We demonstrate that KB treatment attenuated cigarette smoke-induced lung inflammation as shown by
reductions in levels of BAL IFNγ, CXCL9, CXCL10, CCL5, IL-6, G-CSF, and IL-17. KB additionally attenuated the quantity of
BAL lymphocytes and macrophages. In parallel to the attenuation of lung inflammation, KB induced a systemic immune
activation with increases in Ly6CHI monocytes/macrophages and neutrophils.
Conclusions: This is the first demonstration that subcutaneous administration of a microbial-based immunotherapy can
attenuate cigarette smoke-induced lung inflammation, and modulate BAL lymphocyte and macrophage levels, while
inducing a systemic immune activation and mobilization. These data provide a foundation for future studies exploring
how KB may be used to either reverse or prevent progression of established emphysema and small airways disease
associated with chronic cigarette smoke exposure. The data suggest the intriguing possibility that KB, which stimulates
rather than suppresses systemic immune responses, might be a novel means by which the course of COPD pathogenesis
may be altered.
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Background
Chronic obstructive pulmonary disease (COPD) is an in-
flammatory airway disease that results in progressive irre-
versible airflow limitation. The global prevalence of
COPD, as determined by the World Health Organization,
is 11.7% [1], and it is predicted that by 2030 it will be the
fourth leading cause of death worldwide [2]. Mainstream
or second-hand cigarette smoke exposure is a risk factor
for developing COPD [3], which can be exacerbated by
genetic factors [4, 5] and environmental exposures [6, 7].
Chronic cigarette smokers that develop COPD may
present with varying degrees of cough, sputum produc-
tion, dyspnea, wheezing, and chest tightness [8, 9]. Pres-
ently, available treatments primarily focus on suppressing
inflammation and providing bronchodilation. However,
these options have varying efficacy in controlling symp-
toms and do not reverse or limit, completely, the progres-
sion of COPD [10, 11].
The pathology of COPD includes emphysema and ob-
struction of the small airways as a result of chronic bron-
chitis, which is associated with inflammation and immune
dysfunction [12, 13]. In COPD patients, the inflammatory
immune response is altered, and often involves increased
cytokines, including IFN-γ, CXCL9 (MIG), CXCL10
(IP-10), and CCL5 (RANTES) [14–16]. This lung cytokine
and chemokine milieu recruits and activates inflammatory
cells including neutrophils, macrophages, B cells, CD4+ T
cells, and CD8+ T cells [17, 18]. In addition to inflamma-
tion, abnormal immune function has also been described
in COPD patients, including altered macrophage function
[19]. Treatment options that can target the immune
skewing and dysfunction, rather than broad immune
repression, may present a more attractive approach to
manage cigarette smoke-induced COPD.
Treatments strategies using bacterial-derived products
have shown promise in diseases characterized by inflam-
mation and immune dysfunction [20–23]. This has pri-
marily been demonstrated in animal models of allergic
airway disease where different treatment strategies using
bacteria or bacterial derived products have been used to
modulate immune responses [20–22, 24]. Towards that
end, intervention strategies encompassing everything from
live bacteria to specific pattern recognition receptor ago-
nists have been used in models of allergic airway disease
[21, 22, 25–27]. The apparent mechanism of action works
through a reduction in inflammation and an altering of
the immune response. In studies of smoking-induced lung
disease, Lactobacillus rahmnosus and Bifidobacterium
breve have been shown to attenuate pro-inflammatory
cytokine production in a macrophage cell line treated with
cigarette smoke extract [28].
The current study investigated for the first time whether
a novel immunotherapy produced from inactivated
Klebsiella (hereafter referred to as KB) containing all the
major Klebsiella macromolecules, would attenuate mal-
adaptive cigarette smoke exposure-induced immune re-
sponses. We hypothesized that KB would re-direct
damaging immune responses and attenuate cigarette
smoke-induced lung cellular inflammation and bronchoal-
veolar lavage (BAL) cytokine and chemokine production.
We demonstrate that subcutaneous administration of KB
attenuated cigarette smoke-induced lung inflammation
and the quantity of airway BAL lymphocytes and macro-
phages while inducing systemic immune activation mim-
icking the response to acute infection.
Methods
Animals
Female mice C57BL/6 age 8–10 weeks old were purchased
(Jackson Labs, Farmington, Connecticut, USA), acclima-
tized, and housed for one additional week prior to the
commencement of experiments. Female mice were used
as recent studies suggest that they are more susceptible to
cigarette smoke induced lung pathology, as are women
compared to men [29]. The experiments included ten
mice per group, which were housed as five mice per cage
in environmentally-controlled specific pathogen free con-
ditions with a 12:12 h light/dark cycle for the duration of
the study. All protocols were reviewed and approved by
the Animal Care Committee of the University of British
Columbia (Vancouver, BC, Canada).
Cigarette/air smoking protocol
Air or cigarette smoke exposure was done for five con-
secutive days for the first 2 weeks and for four consecutive
days in the third week (experimental days: 1–5; 8–12,
15–18, Fig. 1). Mice were euthanized 24 h after the last ex-
posure (experimental day 19). Briefly, cigarette smoke
exposure (University of Kentucky Research Grade
Cigarettes) was performed by placing mice into plexiglass
“nose only” exposure chambers as previously described
[29, 30]. Each mouse smoked three cigarettes per day for a
total of 45 min of exposure. Control room air-exposed
mice were restrained for a similar duration without expos-
ure to smoke. Animals were monitored throughout the
smoke exposure procedure and for an additional 30 min
post-smoke exposure.
Microbe-based intervention strategy
The microbe-based intervention, KB, is a proprietary im-
munomodulator consisting of all major macromolecules
of an inactivated pathogenic Klebsiella strain was origin-
ally isolated from a patient with acute pneumonia. KB
was supplied by Qu Biologics (Vancouver, BC). For the
treatment intervention, KB or a placebo vehicle control
(physiological saline containing 0.4% phenol) was
prophylactically administered on the experimental day
−7, −5, −3, and the regimen continued throughout the
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experiment on days 1, 3, 5, 8, 10, 12, 15, 17 (Fig. 1). Each
administration involved a subcutaneous injection of
30 μL of placebo or KB, which was alternatively deliv-
ered into the lower right abdomen, the lower left abdo-
men, the upper right chest, and the upper left chest,
rotating clockwise for each injection day.
Blood collection, BAL, and cytospin analysis of BAL cell
differentials
Processing and analysis of collected terminal blood and
BAL samples was done as described previously [22].
Cytospins were performed and cells in BAL evaluated
based on morphology and Wright-Giemsa staining. BAL
cell differentials were then counted using the prepared
cytospin slide with 100 cells per mouse counted in a
blinded fashion.
Immune mediator profiling of BAL and serum samples
Soluble mediator analysis in BAL and serum was
performed using a 31 cytokine, chemokine, growth factor
multiplex kit according to the manufacturer’s protocol
(Millipore, St. Charles, MO, USA) using the Bio-Plex™ 200
system (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
The multiplex was performed by Eve Technologies (Eve
Technologies Corp, Calgary, AB, Canada). The 31-plex
assay included the following mediators: Eotaxin, G-CSF,
GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15,
IL-17, IP-10 (CXCL10), KC (CXCL1), LIF, MCP-1 (CCL2),
M-CSF, MIG (CXCL9), MIP-1α (CCL3), MIP-1β (CCL4),
MIP-2 (CXCL2), RANTES (CCL5), TNFα, and VEGF.
The assay sensitivities of these markers range from 0.1 -
33.3 pg/mL.
Flow cytometric analysis of Ly6CHI monocytes/
macrophages and neutrophils
Blood was collected in EDTA coated tubes (BD
Microtainer) to prevent clotting and stored on ice prior
to staining. Anti-coagulant-treated whole blood was
stained with antibodies (CD11b-FITC, Ly6G-PE, CD11c-
PerCPCy5.5 and Ly6C-APC) before red blood cell lysis
(BD lysis buffer). Flow cytometry was run on a FACSCa-
libur (BD Bioscience). Analysis was completed using the
FlowJo V10.1 program. Neutrophils were defined as
Ly6G+CD11b+ cells. Ly6CHI monocytes/macrophage
were defined as Ly6CHILy6G−CD11b+ cells. Lymphocyte
populations were gated on by forward scatter and side
scatter and then defined as B220+, CD3+CD4+, or CD3
+CD8+.
Data analysis
GraphPad Prism 6 Software (GraphPad Software, San
Diego, CA) was used to perform statistical analysis of
the results. Data are expressed as mean ± SD. One-way
ANOVA analysis followed by multiple comparisons
using a Sidak post-hoc test was performed for group
comparisons. Four experimental group combinations
were compared; room air-placebo vs. room air-KB, room
air-placebo vs. cigarette smoke-placebo, room air-KB vs.
cigarette smoke-KB, cigarette smoke-placebo vs.
cigarette smoke-KB. Differences were reported as statis-
tically significant when p < 0.05.
Results
KB attenuated cigarette smoke exposure-induced influx
of lymphocytes and macrophages, but not neutrophils
into the airways
A three-week acute model of cigarette smoke exposure
in mice (Fig. 1) was used to investigate how KB exposure
can modulate lung inflammation. The total BAL cell
counts and cellular differentials for each experimental
group were assessed (Fig. 2). In placebo treated animals,
cigarette smoke exposure increased the total number of
BAL cells (Fig. 2a, p < 0.0001). The observed increase in
cellularity resulted from increases in the numbers of
lymphocytes, macrophages, and neutrophils (Fig. 2b, d,
p < 0.0001), but not eosinophils (p = 0.35, data not
shown). KB intervention did not significantly decrease
Fig. 1 Cigarette smoke exposure protocol with Klebsiella (KB) intervention. Four groups of mice were exposed to either placebo + room air, KB + room
air, placebo + cigarette smoke, or KB + cigarette smoke. Grey arrows, room air or cigarette smoke; white arrows, subcutaneous injection of placebo or
KB. See methods for details
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the total number of BAL cells, however it did attenuate
the increase in lymphocytes and macrophages in the
cigarette smoke-exposed group (p < 0.005, Fig. 2b-c)
while having no detectable impact on neutrophils
(Fig. 2d, p = 0.59).
KB intervention attenuated cigarette smoke exposure-
induced lung inflammatory responses
Previous reports have demonstrated that cigarette smoke
exposure models are characterized by a cytokine profile
that includes IFN-γ, CXCL9 (MIG), CXCL10 (IP-10), and
CCL5 (RANTES) [14, 15]. A multiplex analysis of 31 cyto-
kines, chemokines, and growth factors (Additional file 1:
Table S1) was used to investigate cytokine and chemokine
production induced by cigarette smoke exposure in this
experimental system. KB intervention had no impact on
air-exposed animals for any mediator measured in the
BAL fluid. Cigarette smoke exposure induced 15 of the 31
measured mediators in the BAL fluid, which were IFNγ,
CXCL9, CXCL10, CCL5, IL-6, IL-17, G-CSF, CXCL1, LIF,
CCL2, CCL3, CCL4, TNFα, eotaxin, and VEGF (p < 0.05).
Although IL-17 was elevated with cigarette smoke
exposure, this was only observed in 4 of 10 samples and
the values were close to the level of detection for this
cytokine (0.64 pg/ml). KB intervention attenuated
cigarette smoke-induced increases in IFNγ, CXCL9,
CXCL10, CCL5, IL-6, G-CSF, and IL-17 (Fig. 3, p < 0.05)
in the BAL fluid. KB also decreased TNFα levels (cigarette
smoke + placebo 7.50 ± 5.98 pg/ml vs cigarette smoke +
KB 3.52 ± 3.34 pg/ml), but this was not statistically
significant (P = 0.057, Additional file 1: Table S1).
Systemic immune cytokine, chemokine and growth factor
profile were not significantly altered with 3-week
cigarette smoke exposure, but were augmented by KB
exposure
When assessing changes in the serum levels of cytokine,
chemokines and growth factors in the experimental treat-
ment groups, it was found that cigarette smoke exposure
induced an increase in only VEGF, and this was not
Fig. 2 KB treatment attenuated cigarette smoke exposure induced increases in airway macrophages and lymphocytes but not total cells or neutrophils.
BAL cell counts and differentials following placebo and KB treatment in room air or cigarette smoke-exposed groups. a BAL total cells, b lymphocytes, c,
macrophages d, and neutrophils. * p< 0.05 comparing to the groups relative control; # p< 0.05 comparing KB group to relative placebo control. Data are
means ± SD of 9–10 mice per group
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changed with the KB intervention (Fig. 4a, p < 0.05;
Additional file 2: Table S2). KB treatment in air-exposed
animals decreased only one mediator, IL12p40, while in-
creasing serum levels of IL-1β, CCL2, CXCL9, and
CXCL10 (Fig. 4b-d, p < 0.05). In the cigarette smoke-
exposed mice, treatment increased the levels of CXCL9,
CXCL10, and CCL5 relative to cigarette smoke + placebo
treated groups (p < 0.05). Collectively these data suggest
that KB intervention induced systemic immune responses
that are independent of cigarette smoke exposure, which
may play a role in the observed local down-regulation of
cigarette smoke exposure-induced lung inflammation.
KB induced both a systemic and local lung tissue increase
in the proportion of Ly6CHI monocytes/macrophages and
neutrophils, with no change in lymphocyte populations
To investigate if the KB intervention altered systemic or
local cellular immune profiles, blood and lung cells were
assessed by flow cytometry, with particular focus on the
levels of Ly6CHI monocytes (an inflammatory subgroup
of monocytes, characterized as Ly6G−CD11b+ cells) and
neutrophils (characterized as Ly6G+CD11b+ cells).
Cigarette smoke exposure had no effects on the numbers
of blood Ly6CHI monocytes or neutrophils (Fig. 5a-b,
p > 0.6). KB intervention increased the blood Ly6CHI
monocytes and neutrophils in the cigarette smoke
exposure groups (p < 0.005), and the neutrophils in the
air-exposed animals (p = 0.05). The increases in systemic
Ly6CHI monocytes and neutrophils were associated with
local increases in the lung tissue (Fig. 5c-d), where KB
induced increases in these cell types, which was further
enhanced by cigarette smoke exposure (p < 0.05).
The levels of B and T lymphocytes were also assessed
in the lungs. The percentage of B cells in the lungs after
smoke exposure was elevated (Fig. 6a, p < 0.05), which
was not attenuated by KB administration. No statistically
significant change in the percentage of CD3+CD4+ or
CD3+CD8+ cells was observed following cigarette smoke
exposure or KB administration (Fig. 6b-c).
Intervention with KB had no impact on clinical score and
body weight following cigarette smoke exposure
Body weight and clinical score was used to monitor the
overall health of mice exposed to cigarette smoke in the
presence or absence of KB. Body weight was normalized
to the starting weight of each animal and all animals were
observed throughout the experiment and their health
assessed based on a clinical score (e.g. hunched posture,
interaction with other animals, activity levels). KB admin-
istration in the air-exposed group did not significantly
alter the body weight (Fig. 7) nor impact the clinical score
(data not shown). No adverse effects of repeated KB ad-
ministration were observed. Cigarette smoke-exposed
mice had a prominent loss in body weight (p < 0.05),
which KB intervention did not attenuate (p > 0.05).
Fig. 3 KB treatment attenuated cigarette smoke exposure induced increases Th1-skewed lung inflammatory responses. BAL supernatant fluid analysis
following placebo and KB treatment in room air or cigarette smoke-exposed groups. a IFNγ, b CXCL9, c CXCL10, d CCL5, e IL-6, f G-CSF, g CXCL1, h
IL-17. * p < 0.05 comparing to the groups relative control; # p < 0.05 comparing KB group to relative placebo control. Data are means ± SD of 10 mice
per group
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Cigarette smoke exposure did not significantly changed
the clinical score for either placebo or KB-treated mice.
Discussion
There is growing awareness that exposure to microbial
products can alter the course of inflammatory diseases. In
asthma, several studies have demonstrated promising re-
sults for resolution of symptoms with microbial products
in both animal models and clinical studies [21, 22, 24–27];
however, there is a paucity of data looking into the use of
these approaches aimed at modulating the course of the
immune dysfunction in COPD [31]. In this study, we
tested the hypothesis that KB, which was produced from a
clinical Klebsiella isolate containing all the major
Klebsiella macromolecules, could modulate airway inflam-
mation and immune responses in a mouse model of acute
cigarette smoke exposure. These results demonstrate that
prophylactic KB treatment attenuated both cigarette
smoke-induced lung inflammation and BAL macrophage
and lymphocyte cellularity. In control room air-exposed
and experimental cigarette smoke-exposed animals, KB
induced systemic immune responses, resulting in
mobilization of monocytes and neutrophils. This systemic
immune modulation was mirrored locally in lung tissue,
reflected by an increase in Ly6CHI monocytes/macro-
phages and neutrophils. These data therefore suggest that
interventions with microbial components that enhance
rather than suppress immune responses may provide a
novel strategy to alter the course of cigarette smoke ex-
posure related COPD pathogenesis. Future therapeutic
intervention-dosing strategies will be aimed at determin-
ing how late in the course of smoke-induced lung damage
such a microbe-based intervention strategy can be admin-
istered to reverse pathology.
Chronic cigarette smoke exposure in humans is associ-
ated with emphysema and chronic bronchitis in COPD
patients. Acute cigarette smoke exposure can lead to in-
flammatory responses that may be important preceding
events in the chronic changes to lung physiology [32]. The
mouse model of acute cigarette smoke exposure used in
this study was designed to determine the impact of KB on
modulating these earlier alterations in the inflammatory
response and not the chronic bronchitic or emphysema-
tous phenotype observed in chronic mouse cigarette
smoke exposure models [29, 33–38]. This study therefore
focused on outcome measurements that are impacted by
Fig. 4 KB treatment differentially modulates cigarette smoke exposure induced changes in serum immune mediators. Serum analysis following placebo
and KB treatment in room air or cigarette smoke-exposed groups. a VEGF, b IL-1β, c CCL2, d CXCL9, e CXCL10 and f CCL5. * p< 0.05 comparing to the
groups relative control; # p< 0.05 comparing KB group to relative placebo control. Data are means ± SD of 9–10 mice per group
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Fig. 5 KB treatment increased blood and lung Ly6CHI monocytes and neutrophils. Flow cytometric analysis of blood a-b and lung c-d Ly6CHI
monocytes and neutrophils following placebo and KB treatment in room air or cigarette smoke-exposed groups. * p < 0.05 comparing to the
groups relative control. # p < 0.05 comparing KB group to relative placebo control. Data are means ± SD of 10 mice per group
Fig. 6 KB treatment has no impact on lung B220+ cells, CD3 + CD4+, or CD3 + CD8+ T cells. Flow cytometric analysis of lung a B220+ B cells, b CD3
+ CD4+ T cells, or c CD3 + CD8+ T cells following placebo and KB treatment in room air or cigarette smoke-exposed groups. * p < 0.05 comparing to
the groups relative control. Data are means ± SD of 10 mice per group
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acute cigarette smoke exposure, including lung in-
flammation resulting from smoke-induced tissue dam-
age, systemic inflammation, immune cell activation,
and body weight.
Cigarette smoke exposure-induced inflammation has
been described as TH1 skewed, although this may be an
over simplification [14, 15]. Changes in inflammatory me-
diators are accompanied by elevations in macrophages,
lymphocytes, and neutrophil populations [17, 18, 32].
IFN-γ has been implicated as an important participant in
the development of emphysematous lesions following
cigarette smoke exposure in mice [16] and has been asso-
ciated with COPD in humans [14, 15]. IFN-γ induces the
CXCR3 ligands, CXCL9 (MIG) and CXCL10 (IP-10) [39]
and the CCR5 ligand, CCL-5 (RANTES) [16] which
recruit lymphocytes and macrophages to sites of inflam-
mation. Importantly, blocking this response protects mice
from the pathological impacts of cigarette smoke exposure
[16, 40]. KB intervention was found to specifically attenu-
ate cigarette smoke-induced elevations in IFN-γ, CXCL9,
CXCL10, CCL-5, and IL-6 in the BAL, which was
uncoupled from systemic immune activation. This reduc-
tion in BAL inflammatory mediators was associated with a
concomitant reduction in macrophage and lymphocyte re-
cruitment to the airways. Future mechanistic studies are
required to determine how modulation of systemic im-
mune function alters the progression of lung immunity
important in chronic models of cigarette smoke exposure.
COPD pathology has many pathologic pathways in
common with other inflammatory diseases, including
asthma and inflammatory bowel disease (IBD). In these
indications, microbial products are actively under investi-
gation as treatment options [23, 24, 31, 41]. IBD and
COPD share common pathology relating to mucosal bar-
rier disruption including an altered microbiome, immune
dysfunction, altered epithelial cell function, and chronic
inflammation [31, 41, 42]. Live microbial products are cur-
rently being tested for efficacy in IBD [43, 44]. Further-
more, a product that is prepared in a similar manner to
KB, but produced from Escherichia coli, has shown
evidence of efficacy in IBD patients [45] and is currently
being investigated in clinical trials as a treatment for IBD.
There is also significant overlap between asthma and
COPD including altered respiratory microbiome and
immune dysfunction [31, 42, 46, 47]. In animal
models of allergic asthma, live bacteria and their
components [24, 27, 48, 49], Toll-like receptor (TLR)
agonists [50], and the KB product [22], have all
reduced lung inflammation. Collectively, the primary
research presented in this report and the studies
outlined above demonstrate some of the similarities
between COPD and other inflammatory diseases that
benefit from microbial intervention strategies. Taken
together, these findings suggest that enhancing or
resetting the immune response with bacterial products
could be a novel therapeutic approach to managing
COPD.
Systemically, these data showed that KB administration,
which contains all the major macromodules from the
Klebsiella, increased certain cytokines conventionally
considered as being pro-inflammatory cytokines, such as
IL-1β, as well as the proportion of blood Ly6CHI
monocytes and neutrophils, similar to the response seen
with an acute infection [51–54]. This immune activation
and mobilization was also detected in the lung tissue by
flow cytometry where an increase in the proportion of
monocytes and neutrophils was observed. Conversely, the
airways of KB treated animals showed a reduction in the
macrophage and lymphocyte levels. This duality of the in-
creased inflammation in the lung tissue and decreased in-
flammation in the airways highlights the importance of
where the immune response occurs for resolution of
Fig. 7 Cigarette smoke exposure impaired body weight gain independent of KB treatment. Daily measurements of mice were normalized to
starting weight for each of the four groups. * p < 0.05 comparing to the group’s relative control. Data are means ± SD of 10 mice per group
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symptoms. Although the precise mechanism(s) of this
phenomenon are not yet clear, the prevailing evidence
suggests that inflammatory monocytes can differentiate
into multiple different cells types in inflamed/damaged
tissue [19, 55, 56] and that enhancement of immune func-
tion in the correct tissue-microenvironment may paradox-
ically contribute to an attenuation in overall inflammation,
potentially by clearing necrotic/damaged tissue and re-
building the loss of barrier function. Indeed, the observed
increase in the number of lung Ly6CHI/CD11b+
inflammatory monocytes may have the ability to suppress
inflammation [56–58].
Conclusions
Our study shows that KB, produced from a clinical
Klebsiella isolate, can suppress the progression of local
airway immune responses and lymphocyte and macro-
phage influx, while inducing a systemic inflammatory
response, in a mouse model of acute cigarette smoke-
induced lung inflammation. This is the first demonstra-
tion that subcutaneous administration of a microbial
derived intervention, KB, can attenuate cigarette smoke-
induced inflammation. These data provide a foundation
for future studies exploring how KB may be used to
either reverse or prevent progression of established
emphysema and small airways disease associated with
chronic cigarette smoke exposure. Lastly, the data
suggest the intriguing possibility that KB, which
stimulates rather than suppresses systemic immune
responses, might be a novel means by which the course
of COPD pathogenesis may be altered, highlighting the
complex interaction between inflammation and COPD
pathogenesis.
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Additional file 1: Table S1. Soluble mediator analysis in BAL fluid
following placebo and KB treatment in room air or cigarette smoke-
exposed groups. * p < 0.05 comparing to the group’s relative control;
# p < 0.05 comparing treated group to untreated relative control. ns
= no significant difference. Data are means ± SD of 9–10 mice per
group. (XLSX 39 kb)
Additional file 2: Table S2. Soluble mediator analysis in serum following
placebo and KB treatment in room air or cigarette smoke-exposed groups. *
p < 0.05 comparing to the group’s relative control; # p < 0.05 comparing
treated group to untreated relative control. ns= no significant difference.
Data are means ± SD of 9–10 mice per group. (XLSX 36 kb)
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